LLY

1,064.11

+2.13%↑

JNJ

234.43

+1.74%↑

ABBV

216.94

+0.77%↑

UNH

388.84

+1.3%↑

AZN

188.07

-0.94%↓

LLY

1,064.11

+2.13%↑

JNJ

234.43

+1.74%↑

ABBV

216.94

+0.77%↑

UNH

388.84

+1.3%↑

AZN

188.07

-0.94%↓

LLY

1,064.11

+2.13%↑

JNJ

234.43

+1.74%↑

ABBV

216.94

+0.77%↑

UNH

388.84

+1.3%↑

AZN

188.07

-0.94%↓

LLY

1,064.11

+2.13%↑

JNJ

234.43

+1.74%↑

ABBV

216.94

+0.77%↑

UNH

388.84

+1.3%↑

AZN

188.07

-0.94%↓

LLY

1,064.11

+2.13%↑

JNJ

234.43

+1.74%↑

ABBV

216.94

+0.77%↑

UNH

388.84

+1.3%↑

AZN

188.07

-0.94%↓

Search

Bio-Techne Corp

Abrir

SetorSaúde

47.91 1.63

Visão Geral

Variação de preço das ações

24h

Atual

Mín

46.52

Máximo

48.09

Indicadores-chave

By Trading Economics

Rendimento

13M

51M

Vendas

16M

311M

P/E

Médio do Setor

63.471

49.701

EPS

0.53

Rendimento de Dividendos

0.74

Margem de lucro

16.392

Funcionários

3,100

EBITDA

22M

100M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+26.87% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

0.74%

2.39%

Próximos Ganhos

5 de ago. de 2026

Próxima data de dividendos

29 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-1.6B

7B

Abertura anterior

46.28

Fecho anterior

47.91

Sentimento de Notícias

By Acuity

50%

50%

148 / 345 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Bio-Techne Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

7 de nov. de 2025, 22:36 UTC

Ganhos

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

Comparação entre Pares

Variação de preço

Bio-Techne Corp Previsão

Preço-alvo

By TipRanks

26.87% parte superior

Previsão para 12 meses

Média 59.25 USD  26.87%

Máximo 70 USD

Mínimo 49 USD

Com base em 10 analistas de Wall Street que oferecem metas de preço de 12 meses para Bio-Techne Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

10 ratings

6

Comprar

4

Manter

0

Vender

Pontuação Técnica

By Trading Central

49.67 / 50.24Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Strong Bearish Evidence

Sentimento

By Acuity

148 / 345 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
help-icon Live chat